Table 1.
Clinical and neuroendocrine outcomes.
| Pre-treatment | Post-treatment | Between Groups Significance | |||||
|---|---|---|---|---|---|---|---|
| Initial | Endpoint | 4-week | Initial to endpoint | Initial to 4-week | |||
| Mean (SD) | Mean (SD) | Mean (SD) | P value | P value | |||
| Clinical | CAPS Score | Drug (n = 4) | 68.75 (10.24) | 43.50 (19.49) | 44.00 (24.12) | 0.425 | 0.047 a |
| Placebo (n = 4) | 68.25 (8.77) | 56.50 (31.89) | 65.25 (18.86) | ||||
| Intrusive Sx | Drug (n = 4) | 13.75 (8.06) | 8.00 (7.70) | 7.50 (9.00) | 0.463 | 0.126 | |
| Placebo (n = 4) | 14.50 (4.65) | 12.00 (10.30) | 15.00 (9.42) | ||||
| Avoidance Sx | Drug (n = 4) | 29.25 (7.14) | 18.75 (11.44) | 17.00 (10.74) | 0.239 | 0.027 b | |
| Placebo (n = 4) | 28.50 (1.29) | 25.50 (7.05) | 26.00 (5.72) | ||||
| Hyperarousal Sx | Drug (n = 4) | 25.75 (0.50) | 16.75 (5.56) | 19.50 (9.68) | 0.786 | 0.359 | |
| Placebo (n = 4) | 25.25 (6.40) | 18.25 (10.53) | 24.25 (5.97) | ||||
| BDI | Drug (n = 4) | 22.25 (5.85) | 13.25 (4.72) | 11.50 (9.15) | 0.124 | 0.769 | |
| Placebo (n = 4) | 24.25 (12.12) | 24.75 (10.05) | 23.75 (9.54) | ||||
| PCL | Drug (n = 4) | 60 (10.83) | 46.75 (11.79) | 49.25 (15.59) | 0.691 | 0.200 | |
| Placebo (n = 4) | 63.25 (11.41) | 54.25 (24.17) | 56.25 (16.68) | ||||
|
| |||||||
| Neuroendocrine | Cortisol (μg/dL) | Drug (n = 4) | 13.15 (3.52) | 31.28 (5.49) | 11.53 (4.27) | 0.001 c | 0.786 |
| Placebo (n = 4) | 12.43 (6.16) | 12.90 (4.87) | 11.83 (2.91) | ||||
| ACTH (pg/mL) | Drug (n = 4) | 49.33 (29.69) | 153.45 (40.25) | 53.63 (8.08) | 0.009 d | 0.785 | |
| Placebo (n = 4) | 30.88 (14.83) | 38.40 (16.18) | 41.63 (19.33) | ||||
| Lysozyme IC50 (nM) | Drug (n = 2) | 8.00 (2.55) | 5.57 (.76) | 6.73 (3.66) | 0.162 | 0.411 | |
| Placebo (n = 4) | 3.27 (2.89) | 3.65 (2.06) | 5.03 (1.68) | ||||
| GR/cell | Drug (n = 3) | 1557.67 (539.75) | 188.67 (116.89) | 1593.00 (770.02) | 0.003 | 0.322 | |
| Placebo (n = 4) | 1019.50 (553.91) | 1243.00 (543.84) | 1824.75 (683.80) | ||||
aMedian change in CAPS score for mifepristone group (20.0); median change in CAPS score for placebo group (10.5); nonparametric P value (0.021).
bMedian change in CAPS avoidance symptom score for mifepristone group (11.0); median change in CAPS avoidance symptom score for placebo group (4.0); nonparametric P value (0.028).
cMedian change in cortisol for mifepristone group (17.2); median change in cortisol for placebo group (0.4); nonparametric P value (0.021).
dMedian change in ACTH for mifepristone group (90.6); median change ACTH for placebo group (4.2); nonparametric P value (0.021).